Therapeutic vaccines and cancer: focus on DPX-0907

References

• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• KlebanoffCAGattinoniLRestifoNPCD8+ T-cell memory in tumor immunology and immunotherapyImmunol Rev200621121422416824130
   PubMed Web of Science ®Google Scholar
• PerretRRoncheseFMemory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?Tissue Antigens200872318719418627571
   PubMedGoogle Scholar
• GattinoniLKlebanoffCARestifoNPPaths to stemness: building the ultimate antitumour T cellNat Rev Cancer2012121067168422996603
   PubMed Web of Science ®Google Scholar
• DobrzanskiMJExpanding roles for CD4 T cells and their subpopulations in tumor immunity and therapyFront Oncol201336323533029
   PubMedGoogle Scholar
• PardollDMTopalianSLThe role of CD4+ T cell responses in antitumor immunityCurr Opin Immunol19981055885949794842
   PubMed Web of Science ®Google Scholar
• van der BurgSHBijkerMSWeltersMJOffringaRMeliefCJImproved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacyAdv Drug Deliv Rev200658891693016979788
   PubMed Web of Science ®Google Scholar
• van der BurgSHVisserenMJBrandtRMKastWMMeliefCJImmunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stabilityJ Immunol19961569330833148617954
   PubMed Web of Science ®Google Scholar
• KarkadaMWeirGMQuintonTA novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responsesJ Immunother201033325026120445345
   PubMed Web of Science ®Google Scholar
• BerinsteinNLKarkadaMMorseMAFirst-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patientsJ Transl Med20121015616822862954
   PubMed Web of Science ®Google Scholar
• SlingluffCLJrYamshchikovGNeesePPhase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomesClin Cancer Res20017103012302411595689
   PubMed Web of Science ®Google Scholar
• DaftarianPMansourMBenoitACEradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsionVaccine200624245235524416675074
   PubMed Web of Science ®Google Scholar
• KarkadaMQuintonTBlackmanRMansourMTumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory/suppressor cell proliferation and tumor infiltrationISRN Oncol2013201375342723533812
   PubMedGoogle Scholar
• MansourMPohajdakBKastWMTherapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMaxJ Transl Med20075202617451606
   PubMed Web of Science ®Google Scholar
• MacDonaldLDFuentes-OrtegaASammaturLMansourMEfficacy of a single dose hepatitis B depot vaccineVaccine201028447143714520832491
   PubMed Web of Science ®Google Scholar
• RamakrishnaVRossMMPeterssonMNaturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cellsInt Immunol200315675176312750359
   PubMed Web of Science ®Google Scholar
• MorseMASecordAABlackwellKMHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerClin Cancer Res201117103408341921300761
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• SinnathambyGZerfassJHafnerJADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancersClin Exp Immunol2011163332433221175594
   PubMed Web of Science ®Google Scholar
• SinnathambyGZerfassJHafnerJEDDR1 is a potential immunotherapeutic antigen in ovarian, breast, and prostate cancerJ Clin Cell Immunol20112118
   Google Scholar
• PillaLRivoltiniLPatuzzoRMarrariAValdagniRParmianiGMultipeptide vaccination in cancer patientsExpert Opin Biol Ther2009981043105519591629
   PubMed Web of Science ®Google Scholar
• LévyFColombettiSPromises and limitations of murine models in the development of anticancer T-cell vaccinesInt Rev Immunol2006255–626929517169777
   PubMed Web of Science ®Google Scholar
• NewbergMHSmithDHHaertelSBViningDRLacyEEngelhardVHImportance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC moleculesJ Immunol19961567247324808786307
   PubMed Web of Science ®Google Scholar
• BinaschiMBigioniMCipolloneAAnthracyclines: selected new developmentsCurr Med Chem Anticancer Agents20011211313012678762
   PubMedGoogle Scholar
• Heinzelmann-SchwarzVAGardiner-GardenMHenshallSMOverexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancerClin Cancer Res200410134427443615240533
   PubMed Web of Science ®Google Scholar
• ShimadaKNakamuraMIshidaEProstate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancerCancer Sci2008991394517970783
   PubMed Web of Science ®Google Scholar
• AppayVDouekDCPriceDACD8+ T cell efficacy in vaccination and diseaseNat Med200814662362818535580
   PubMed Web of Science ®Google Scholar
• JägerEJägerDKnuthAAntigen-specific immunotherapy and cancer vaccinesInt J Cancer2003106681782012918057
   PubMed Web of Science ®Google Scholar
• ChiangCLKandalaftLECoukosGAdjuvants for enhancing the immunogenicity of whole tumor cell vaccinesInt Rev Immunol2011302–315018221557641
   PubMed Web of Science ®Google Scholar
• TakahashiNOhkuriTHommaSFirst clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigenCancer Sci2012103115015322221328
   PubMed Web of Science ®Google Scholar
• DisisMLSchiffmanKGuthrieKEffect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccineJ Clin Oncol200422101916192515143085
   PubMed Web of Science ®Google Scholar
• KanodiaSKastWMPeptide-based vaccines for cancer: realizing their potentialExpert Rev Vaccines20087101533154519053209
   PubMed Web of Science ®Google Scholar
• Pejawar-GaddySFinnOJCancer vaccines: accomplishments and challengesCrit Rev Oncol Hematol20086729310218400507
   PubMed Web of Science ®Google Scholar
• van der BurgSHPiersmaSJde JongAAssociation of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigensProc Natl Acad Sci U S A200710429120871209217615234
   PubMed Web of Science ®Google Scholar
• Chianese-BullockKAIrvinWPJrPetroniGRA multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancerJ Immunother200831442043018391753
   PubMed Web of Science ®Google Scholar
• PeralesMAYuanJPowelSPhase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanomaMol Ther200816122022202918797450
   PubMed Web of Science ®Google Scholar
• BernhardtSLGjertsenMKTrachselSTelomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBr J Cancer200695111474148217060934
   PubMed Web of Science ®Google Scholar
• HolmesJPBenavidesLCGatesJDResults of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccineJ Clin Oncol200826203426343318612158
   PubMed Web of Science ®Google Scholar
• DiefenbachCSGnjaticSSabbatiniPSafety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionClin Cancer Res20081492740274818451240
   PubMed Web of Science ®Google Scholar
• OdunsiKQianFMatsuzakiJVaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProc Natl Acad Sci U S A200710431128371284217652518
   PubMed Web of Science ®Google Scholar
• SpisekRImmunoprevention of cancer: time to reconsider timing of vaccination against cancerExpert Rev Anticancer Ther20066121689169117181481
   PubMed Web of Science ®Google Scholar